^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Liposarcoma
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Dedifferentiated liposarcoma: Useful in certain circumstances…Palbociclib